Related Experiment Video
Updated: Jul 19, 2025
Plasma Polishing as a New Polishing Option to Reduce the Surface Roughness of Porous Titanium Alloy for 3D Printing
Published on: April 28, 2023
Cold atmospheric plasma treated 3D printed polylactic acid film; application in thin film solid phase microextraction
Hadiseh Rezaei1, Amir Abbas Matin1, Mohsen Mohammadnejad2
1Department of Chemistry, Faculty of Basic Sciences, Azarbaijan Shahid Madani University, Tabriz, Iran.
Abstract:
Tyrosine Kinase Inhibitors (TKIs) represent a pharmacological category of targeted therapeutics deployed for the treatment of malignant pathologies. Considering the side effects of this class of drugs for humans, therapeutic drug monitoring (TDM) becomes important. Here, a novel and specific methodology is introduced for the quantification of two TKIs (dasatinib and erlotinib) in human plasma samples. Furthermore, this study investigates the successful application of 3D printer technology in analytical sample preparation methods. Employing a fused deposition modeling (FDM) 3D printer and polylactic acid (PLA) filament, adsorbent films were designed and produced to be utilized in thin film microextraction. The 3D printed polylactic acid film surface was modified using cold atmospheric plasma (CAP) as a fast, clean and dry surface modification method with low consumption of chemicals and energy. Subsequently, FESEM, AFM, ATR-FTIR, and WCA analysis studies were employed to effectively assess the efficacy of the plasma surface modification method for the 3D printed films. After the optimization of the plasma modification and extraction methods, human plasma samples were studied for the effectiveness of the aforementioned approach. So, the selected 3D printed films with excellent microextraction efficiency have been found to be effective in sample preparation of biological samples. The linear dynamic range (LDR), limit of detection (LOD) and limit of quantification (LOQ) were obtained 0.10-20 μgL-1, 0.03 μgL-1and 0.1 μgL-1 for dasatinib and 1.0-500 μgL-1, 0.3 μgL-1, and 1 μgL-1 for erlotinib. The results obtained indicate that the developed method proves to be successful in the effective separation of anticancer drugs.
Insights
This study introduces a novel method using 3D-printed films and plasma technology for quantifying tyrosine kinase inhibitors (TKIs) in human plasma. This approach enhances therapeutic drug monitoring for anticancer treatments.
Area of Science:
- Analytical Chemistry
- Materials Science
- Pharmacology
Background:
- Tyrosine Kinase Inhibitors (TKIs) are crucial targeted therapies for cancer.
- Therapeutic Drug Monitoring (TDM) is essential due to TKI side effects.
- Advanced analytical methods are needed for precise TKI quantification in biological samples.
Purpose of the Study:
- To develop and validate a novel method for quantifying dasatinib and erlotinib in human plasma.
- To investigate the application of 3D printing technology in analytical sample preparation.
- To assess the efficacy of cold atmospheric plasma (CAP) for surface modification of 3D-printed extraction films.
Main Methods:
- Fused Deposition Modeling (FDM) 3D printing of polylactic acid (PLA) films for thin film microextraction.
- Surface modification of PLA films using cold atmospheric plasma (CAP).
- Characterization of modified films using FESEM, AFM, ATR-FTIR, and WCA.
- Optimization and validation of the microextraction and quantification method for TKIs in human plasma.
Main Results:
- 3D-printed PLA films modified with CAP demonstrated excellent microextraction efficiency.
- The method achieved sensitive quantification of dasatinib (LDR: 0.10-20 μgL⁻¹, LOD: 0.03 μgL⁻¹, LOQ: 0.1 μgL⁻¹) and erlotinib (LDR: 1.0-500 μgL⁻¹, LOD: 0.3 μgL⁻¹, LOQ: 1 μgL⁻¹).
- The developed approach proved effective for sample preparation and separation of anticancer drugs in biological matrices.
Conclusions:
- 3D printing combined with CAP surface modification offers a promising tool for creating efficient microextraction devices.
- The developed analytical method is suitable for therapeutic drug monitoring of TKIs in human plasma.
- This innovative approach facilitates the precise quantification of anticancer drugs, aiding in personalized medicine and treatment optimization.
